Evaluation of 99mTc-bis-Cysteamide Folate as a New Receptor-Targeted Imaging Agent in Diagnosing Breast Cancer

Evaluation of 99mTc-bis-Cysteamide Folate as a New Folate Receptor-Targeted Imaging Agent in Diagnosing Breast Cancer and differentiating benign from malignant masses in women with breast masses of unknown nature

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171231038164N1

Enrollment

Registered

2021-02-18

Start date

2016-11-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast mass. Breast mass, breast cancer, folate receptor, 99m tc bis-folate cysteamide,folate targeted diagnostic imaging

Interventions

Intervention group: We used 99mTc-bis-cysteamide folate, a derivative of folic acid, for evaluation of avidity of breast masses of unknown nature in 31 patients. This radiopharmaceutical has been syn

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with breast mass Unknown nature of breast mass

Exclusion criteria

Exclusion criteria: FNA of breast in the recent 2 weeks Biopsy of breast in the recent month Surgery on breast in the recent 2 months Folic acid consumption in the recent 2 weeks Recent chemoradiotherapy in the recent 2 months Pregnancy/ breast feeding

Design outcomes

Primary

Measure	Time frame
Number of patients with breast mass of unknown nature. Timepoint: Performing scintimammography 3 hours post radiotracer injection. Method of measurement: Visual and quantitative analysis of radiotracer uptake by nuclear medicine physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrosadat Alavi

Shiraz University of Medical Sciences

Alavimh@sums.ac.ir+98 71 3647 4333

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026